Skip to main content
This block is broken or missing. You may be missing content or you might need to enable the original module.
Search
English
Svenska
Français
Deutsch
Español
Italiano
Português
Main sub menu
Investors
Investor relations
Extraordinary General Meeting 2021
Annual Report 2019
The share
Financial news
Presentations
Financials
Corporate governance
Careers
Working at Recipharm
The Recipharm story
Meet our employees
Current vacancies
Contact
Contact us
Development services contacts
Manufacturing services contacts
Locations
France
Fontaine
Kaysersberg
Monts
Pessac
Germany
Monheim
Wasserburg
Zwickau
India
Bengaluru
Karnal / Paonta Sahib
Israel
Ness Ziona
Italy
Brescia
Lainate
Masate
Paderno Dugnano
Pianezza
Portugal
Odivelas
Queluz
Spain
Parets
Leganés
Sweden
Höganäs
Stockholm city (HQ)
Karlskoga
Solna
Strängnäs
Uppsala
Uppsala Development
UK
Cramlington
Holmes Chapel
Queenborough
King’s Lynn
USA
Research Triangle Park
Main navigation
Development
Drug substance
Drug product
Analytical chemistry
Clinical trial material (CTM)
Manufacturing
Solids
Semi-solids
Liquids
Inhalation
Injectables
Ophthalmics
Solutions
Recipharm Analytical Solutions™
Recipharm Inhalation Solutions™
Recipharm Pathway to Clinic®
Serialisation
Bespak
Learn
Press & events
Press
Events
Reports
Insights
Our story
Recipharm in brief
Business model
Sustainability
Company history
Investor relations
Financial news
Financial information
Financial press
Financial events
Financial reports
Displaying 1 - 10 of 154
Show all
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Financial Press
Delisting of shares from Nasdaq Stockholm
2021.02.19
Read more
Financial Press
Notice of extraordinary general meeting in Recipharm AB (publ)
2021.02.16
Read more
Financial Press
Recipharm applies for delisting of shares and summons to extraordinary general meeting
2021.02.15
Read more
Financial Press
Results of meeting of the holders of Recipharm convertible bonds: consent granted to correct error in terms and conditions
2021.02.03
Read more
Financial Press
Statement by the Board of Directors of Recipharm regarding the public offer from Roar BidCo
2021.01.28
Read more
Financial Press
Recipharm has convened a bondholder meeting to correct the terms and conditions of its convertible bonds and announces date for a preliminary 2020 year-end report
2021.01.11
Read more
Financial Press
Announcement of consent solicitation by Recipharm AB (publ) in respect of its SEK 1,000,000,000 Senior Unsecured Convertible Bonds due 2021 (ISIN: XS1496895753)
2021.01.11
Read more
Financial Press
Recipharm and Moderna finalize agreement for aseptic drug product manufacturing and fill-finish for supply to countries outside the U.S.
2020.12.30
Read more
Financial Press
Comment from Recipharm’s board of directors regarding the public offer from Roar BidCo and correction of error in convertible bond terms
2020.12.14
Read more
Financial Press
Recipharm announces signature of letter of intent for aseptic fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate (mRNA-1273)
2020.11.24
Read more
Pagination
Current page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
Next ›
Last page
Last »